HLS Therapeutics Inc is seeing a positive uptick in its stock price, reflecting investor optimism.
HLS Therapeutics Inc (HLS.TO) has experienced a notable rise of 1.17% in its stock price during the last trading session, closing at CA$4.34. This increase comes amidst steady revenue growth and positive market sentiment towards the companyโs product lines, particularly Vascepa.
Investor takeaway: Investors may find HLS Therapeutics appealing as it shows resilience and growth potential, especially in its core products, which are gaining traction in the market.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$131.35M
52W high
$5.76
52W low
$4.00
1W change
-2.10%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 73.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.27
+73.1% Upside
Current Price
C$4.20
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.9%
Annualized
90-Day Vol
22.6%
Annualized
Trend (90d)
-42.7%
Annualized drift
90d Mean
C$3.61
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.99 | C$3.60 โ C$4.43 |
| 60 trading days | C$3.79 | C$3.28 โ C$4.39 |
| 90 trading days | C$3.61 | C$3.02 โ C$4.31 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc's stock rises by 1.17% in one day.
With a market cap of CA$137.3 million, HLS Therapeutics is navigating a competitive pharmaceutical landscape while managing its financial metrics.
Bull case
The recent 2% year-over-year revenue growth reported for Q1 2026, along with a significant 15% increase in Vascepa net sales, suggests that HLS Therapeutics is on a positive trajectory. This growth could boost investor confidence and attract more interest in the stock.
Bear case
Despite the positive movement, HLS Therapeutics still faces challenges, including a negative profit margin of -18.46%. Investors should be cautious about the company's overall financial health and market volatility.
Recent Performance Overview
HLS Therapeutics Inc's stock closed at CA$4.34 after a 1.17% increase in the last trading session. This upward movement is a positive sign for investors, especially considering the company's recent revenue growth.
Growth Drivers Behind the Stock Surge
The company's flagship product, Vascepa, has seen a 15% increase in net sales year-over-year, significantly contributing to the overall revenue growth of 2% reported for Q1 2026. This performance indicates that HLS Therapeutics is effectively capitalizing on its market opportunities.
Looking Ahead
As HLS Therapeutics prepares for its upcoming financial results conference call on May 15, 2026, investors will be eager to hear more about the company's strategy moving forward. The focus will likely remain on how it plans to enhance product sales and improve its financial standing.
Advertisement
